AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23648048 — intervention group
Group type: EXPERIMENTAL
Intervention: San Diego parks
Number of subjects: 20
Study 23648048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood walkability
Number of subjects: 20
Study 23648048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood income
Number of subjects: 20
Study 23648048 — intervention group
Group type: COMPARATOR
Intervention: Parks in Ghent
Number of subjects: 20
Study 20021992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall obesity (BMI)
Number of subjects: 2547
Study 20021992 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (visceral fat)
Number of subjects: 2547
Study 20021992 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat (adjusted for BMI)
Number of subjects: 2547
Study 20021992 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms
Number of subjects: 2547
Study 20021992 — intervention group
Group type: COMPARATOR
Intervention: No associations found in women
Number of subjects: 2547
Study 18361004 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 35
Study 18361004 — intervention group
Group type: EXPERIMENTAL
Intervention: Case series of ECMO
Number of subjects: 35
Study 18361004 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO as rescue therapy
Number of subjects: 35
Study 16875188 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (carpal tunnel release)
Number of subjects: 0
Study 16875188 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (immobilization, physiotherapy, drug therapy, steroid injections)
Number of subjects: 0
Study 16875188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-invasive measures
Number of subjects: 0
Study 12491501 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone)
Number of subjects: 441
Study 12491501 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (L-phenylalanine mustard)
Number of subjects: 441
Study 12491501 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (in premenopausal women)
Number of subjects: 441
Study 12491501 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (in premenopausal women)
Number of subjects: 441
Study 12491501 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (in patients with > or = 4 positive lymph nodes)
Number of subjects: 441
Study 12491501 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (in patients with > or = 4 positive lymph nodes)
Number of subjects: 441
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence at age 6
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence at age 12
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence at age 15
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence at age 16 to 18
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopia prevalence at age 18
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean refractive status at age 18
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length progression
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber depth (ACD)
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal curvature
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens thickness progression
Number of subjects: 11178
Study 10375241 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of myopia severity between genders
Number of subjects: 11178
Study 8942777 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review
Number of subjects: 400
Study 8942777 — intervention group
Group type: EXPERIMENTAL
Intervention: Editing
Number of subjects: 400
Study 1497689 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISMN in the morning
Number of subjects: 382
Study 1497689 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISMN b.i.d. morning and early afternoon
Number of subjects: 382
Study 1497689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 382
Study 6128331 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (40 g, i.v.)
Number of subjects: 40
Study 6128331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 40
Study 31711373 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (highest category)
Number of subjects: 264211
Study 31711373 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern (highest category)
Number of subjects: 264211
Study 31711373 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern
Number of subjects: 264211
Study 31711373 — intervention group
Group type: EXPERIMENTAL
Intervention: Western/unhealthy dietary pattern
Number of subjects: 264211
Study 30742614 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanitation intervention (pit latrine with plastic slab and drophole cover, child feces management tools)
Number of subjects: 2107
Study 30742614 — intervention group
Group type: COMPARATOR
Intervention: Control (no sanitation intervention)
Number of subjects: 2107
Study 30742614 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanitation intervention
Number of subjects: 2107
Study 30742614 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2107
Study 28408193 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (25-75 mg daily for 10 weeks)
Number of subjects: 138
Study 28408193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 28408193 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138
Study 26337625 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, task-specific upper limb training intervention
Number of subjects: 24
Study 26337625 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered sessions
Number of subjects: 24
Study 26337625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-practice recommended for 42 hours
Number of subjects: 24
Study 24399266 — intervention group
Group type: EXPERIMENTAL
Intervention: Household preparedness education through 'promotora' led small group meetings
Number of subjects: 187
Study 24399266 — intervention group
Group type: COMPARATOR
Intervention: Household preparedness education through print media
Number of subjects: 187
Study 18955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine model
Number of subjects: 49
Study 18955605 — intervention group
Group type: COMPARATOR
Intervention: Manikin model
Number of subjects: 49
Study 14996520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004% travoprost
Number of subjects: 34
Study 14996520 — intervention group
Group type: COMPARATOR
Intervention: 0.005% latanoprost
Number of subjects: 34
Study 14996520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 34
Study 11759980 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg oral misoprostol every 4 hours
Number of subjects: 89
Study 11759980 — intervention group
Group type: COMPARATOR
Intervention: 50 mcg oral misoprostol every 6 hours
Number of subjects: 89
Study 11759980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 9158880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (SD) MDL 26479 ranging from 2 to 465 mg
Number of subjects: 0
Study 9158880 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD) MDL 26479 at doses of 30, 60, and 120 mg administered twice daily for 28 days
Number of subjects: 0
Study 9158880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (SD) and multiple-dose (MD) MDL 26479
Number of subjects: 0
Study 7962378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile subcutaneous gonadotrophin administration
Number of subjects: 75
Study 7962378 — intervention group
Group type: COMPARATOR
Intervention: Single daily bolus intramuscular gonadotrophin administration
Number of subjects: 75
Study 3656939 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration dialysate (H; Na 154 mmol/liter)
Number of subjects: 12
Study 3656939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration dialysate (L; Na 126 mmol/liter)
Number of subjects: 12
Study 3656939 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal concentration dialysate (N; Na 140 mmol/liter)
Number of subjects: 12
Study 3656939 — intervention group
Group type: COMPARATOR
Intervention: Post-dialysis mean arterial pressure
Number of subjects: 12
Study 3656939 — intervention group
Group type: COMPARATOR
Intervention: Heart rate during dialysis
Number of subjects: 12
Study 11552204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa L-dopa (Sinemet)
Number of subjects: 4
Study 30659043 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to remote, urgent, digital histopathology service
Number of subjects: 0
Study 30423848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index potato (Carisma® low GI)
Number of subjects: 20
Study 30423848 — intervention group
Group type: COMPARATOR
Intervention: High Glycaemic Index potato (Arizona high GI)
Number of subjects: 20
Study 26443493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care trauma-focused cognitive behavioral therapy (SC-TF-CBT)
Number of subjects: 53
Study 26443493 — intervention group
Group type: COMPARATOR
Intervention: Standard trauma-focused cognitive behavioral therapy (TF-CBT)
Number of subjects: 53
Study 26443493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC-TF-CBT and TF-CBT
Number of subjects: 53
Study 24413262 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antiretroviral prophylaxis among replacement-feeding mothers with baseline BMI at least 25
Number of subjects: 797
Study 24413262 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antiretroviral prophylaxis among breastfeeding mothers who ceased breastfeeding before 3 months postpartum with baseline BMI at least 25
Number of subjects: 797
Study 24413262 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding up to 6 months postpartum
Number of subjects: 797
Study 22764364 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone implant
Number of subjects: 100
Study 22764364 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 100
Study 21400797 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 42
Study 21400797 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of analgesics and anaesthetics
Number of subjects: 42
Study 18268929 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 5 microg Respimat
Number of subjects: 202
Study 18268929 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 20 microg Respimat
Number of subjects: 202
Study 18268929 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 18 microg HandiHaler
Number of subjects: 202
Study 18268929 — intervention group
Group type: COMPARATOR
Intervention: placebo Respimat
Number of subjects: 202
Study 18268929 — intervention group
Group type: COMPARATOR
Intervention: placebo HandiHaler
Number of subjects: 202
Study 16044227 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatally-displaced canines
Number of subjects: 115
Study 16044227 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilaterally-affected patients
Number of subjects: 115
Study 12390549 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 138
Study 10426243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block using 10 mL of 2% lignocaine
Number of subjects: 100
Study 10426243 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study 7564725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate (900 mg) and metoclopramide (10 mg)
Number of subjects: 421
Study 7564725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (100 mg)
Number of subjects: 421
Study 7564725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 7564725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate and metoclopramide
Number of subjects: 421
Study 2405540 — intervention group
Group type: EXPERIMENTAL
Intervention: Phadirect Strep A rapid test
Number of subjects: 257
Study 2405540 — intervention group
Group type: COMPARATOR
Intervention: Cultivation at microbiological laboratories
Number of subjects: 257
Study 6105569 — intervention group
Group type: EXPERIMENTAL
Intervention: Index group (24 trainees) received four sessions of individual instruction based on videotaped feedback.
Number of subjects: 45
Study 6105569 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 trainees) did not receive the intervention.
Number of subjects: 45
Study 30768732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/day (eGFR ≥ 50 mL/min/1.73 m2)
Number of subjects: 0
Study 30768732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg/day (eGFR 30-49 mL/min/1.73 m2)
Number of subjects: 0
Study 30768732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (eGFR ≥ 50 mL/min/1.73 m2)
Number of subjects: 0
Study 30768732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (eGFR 30-49 mL/min/1.73 m2)
Number of subjects: 0
Study 30768732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (eGFR 30-49 mL/min/1.73 m2)
Number of subjects: 0
Study 27781307 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks heavy resistance training
Number of subjects: 15
Study 27781307 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 27781307 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heavy resistance training
Number of subjects: 15
Study 25700288 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) target <150 mm Hg
Number of subjects: 53
Study 25700288 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) target <180 mm Hg
Number of subjects: 53
Study 23053684 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Program (ASMP)
Number of subjects: 104
Study 23053684 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 23053684 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Program (ASMP) with attendance of four or more classes
Number of subjects: 104
Study 23053684 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Program (ASMP) with attendance of less than four classes
Number of subjects: 104
Study 23053684 — intervention group
Group type: COMPARATOR
Intervention: Both ASMP and usual care groups
Number of subjects: 104
Study 21083585 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (given orally for 6 days preoperatively and 10 days post-operatively)
Number of subjects: 100
Study 21083585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 100
Study 20008376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellie the Elephant
Number of subjects: 130
Study 20008376 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 130
Study 20008376 — intervention group
Group type: COMPARATOR
Intervention: That's the Way (I like it)
Number of subjects: 130
Study 17921531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stent
Number of subjects: 91
Study 17921531 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 91
Study 15465627 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of genes located on chromosome 10 involved in cholesterol metabolism (LIPA, CH25H, FLJ22476)
Number of subjects: 286
Study 15465627 — intervention group
Group type: COMPARATOR
Intervention: Control group (162 individuals without AD)
Number of subjects: 286
Study 11460544 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid cream (8% concentration)
Number of subjects: 0
Study 11460544 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid cream (4% concentration)
Number of subjects: 0
Study 11460544 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (vehicle)
Number of subjects: 0
Study 9879196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia with prostaglandin E1 (PGE1) and autologous blood transfusion (400 ml)
Number of subjects: 137
Study 7980301 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium sulphate and nifedipine regimen
Number of subjects: 91
Study 7980301 — intervention group
Group type: COMPARATOR
Intervention: lytic cocktail and nifedipine group
Number of subjects: 91
Study 2498955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine
Number of subjects: 28
Study 2498955 — intervention group
Group type: EXPERIMENTAL
Intervention: saline
Number of subjects: 28
Study 2498955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg scopolamine
Number of subjects: 28
Study 31679744 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based transitional care program (6 weeks)
Number of subjects: 242
Study 31679744 — intervention group
Group type: COMPARATOR
Intervention: Attentional control (two general health education classes and post-discharge social calls)
Number of subjects: 242
Study 31708253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pityriasis Alba group (cases)
Number of subjects: 110
Study 31708253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 29602555 — intervention group
Group type: EXPERIMENTAL
Intervention: General plus regional anesthesia
Number of subjects: 711
Study 29602555 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia alone
Number of subjects: 711
Study 28974258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention text messages about contraception and behaviour change methods delivered over 4 months.
Number of subjects: 570
Study 28974258 — intervention group
Group type: COMPARATOR
Intervention: Control text messages about trial participation.
Number of subjects: 570
Study 26665759 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy combined with Prolit super septo (10 day course)
Number of subjects: 120
Study 26665759 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 120
Study 24195622 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 9
Study 21978016 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniFit Personal Coach (CPC)
Number of subjects: 0
Study 21978016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Acceleration Program (RAP)
Number of subjects: 0
Study 21978016 — intervention group
Group type: COMPARATOR
Intervention: Control group of regular readers
Number of subjects: 0
Study 19092036 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 0
Study 19092036 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study 17225620 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 38
Study 17225620 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 38
Study 12609560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day plus CR BNO 1055 (20 mg of herbal drug) for 12 months (intervention group, n=90)
Number of subjects: 136
Study 12609560 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day (usual-care group, n=46)
Number of subjects: 136
Study 11103179 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 45
Study 11103179 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 45
Study 11103179 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 9466128 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of fish oil per day
Number of subjects: 58
Study 9466128 — intervention group
Group type: COMPARATOR
Intervention: 0 g of fish oil (placebo)
Number of subjects: 58
Study 9466128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of fish oil per day
Number of subjects: 58
Study 9466128 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of fish oil per day
Number of subjects: 58
Study 8448746 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300-400 mg/d for 2 years)
Number of subjects: 112
Study 8448746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 3008055 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and citrovorum factor rescue
Number of subjects: 71
Study 3008055 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 71
Study 31109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (4.8 g) three times a day for 12 weeks
Number of subjects: 0
Study 31109001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26486857 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Short Messaging Service (SMS) reminders for 2 months, including personalized daily medication reminders and twice weekly health information SMS.
Number of subjects: 200
Study 26486857 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study 26486857 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Short Messaging Service (SMS) reminders for 2 months.
Number of subjects: 200
Study 23396493 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB) using an Eliminate catheter
Number of subjects: 141
Study 23396493 — intervention group
Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB)
Number of subjects: 141
Study 21177789 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg) given subcutaneously once weekly for 3 weeks
Number of subjects: 33
Study 21177789 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg)
Number of subjects: 33